VivoSeq
Infectious Disease

Epstein Barr Virus

0

Pipeline Programs

13

Active Trials

2

Companies Involved

Epstein Barr Virus is an early-stage landscape with 0 programs across 2 companies. The most active players are Moderna, Atara Biotherapeutics.

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

24

clinical trials

Completed6 · 25%
Active, not recruiting5 · 21%
Recruiting5 · 21%
Unknown status4 · 17%
Not yet recruiting2 · 8%
No longer available1 · 4%
Other1 · 4%

Trial Activity

24 trials

Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)